These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31036006)

  • 1. Effect of transcription inhibition and generation of suppressive viral non-coding RNAs.
    Pinto DO; Scott TA; DeMarino C; Pleet ML; Vo TT; Saifuddin M; Kovalskyy D; Erickson J; Cowen M; Barclay RA; Zeng C; Weinberg MS; Kashanchi F
    Retrovirology; 2019 Apr; 16(1):13. PubMed ID: 31036006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7791-6. PubMed ID: 10393900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Transcription Inhibitors Increase the Synthesis of Viral Non-Coding RNA that Contribute to Latency.
    Akpamagbo YA; DeMarino C; Pleet ML; Schwab A; Rodriguez M; Barclay RA; Sampey G; Iordanskiy S; El-Hage N; Kashanchi F
    Curr Pharm Des; 2017; 23(28):4133-4144. PubMed ID: 28641535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2.
    García-Martínez LF; Mavankal G; Peters P; Wu-Baer F; Gaynor RB
    J Mol Biol; 1995 Dec; 254(3):350-63. PubMed ID: 7490754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.
    Ivanov D; Kwak YT; Nee E; Guo J; García-Martínez LF; Gaynor RB
    J Mol Biol; 1999 Apr; 288(1):41-56. PubMed ID: 10329125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.
    Mousseau G; Aneja R; Clementz MA; Mediouni S; Lima NS; Haregot A; Kessing CF; Jablonski JA; Thenin-Houssier S; Nagarsheth N; Trautmann L; Valente ST
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.
    Wu-Baer F; Sigman D; Gaynor RB
    Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7153-7. PubMed ID: 7638159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription.
    Agbottah E; Deng L; Dannenberg LO; Pumfery A; Kashanchi F
    Retrovirology; 2006 Aug; 3():48. PubMed ID: 16893449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies.
    Rice AP
    Curr Pharm Des; 2017; 23(28):4098-4102. PubMed ID: 28677507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PJA2 ubiquitinates the HIV-1 Tat protein with atypical chain linkages to activate viral transcription.
    Faust TB; Li Y; Jang GM; Johnson JR; Yang S; Weiss A; Krogan NJ; Frankel AD
    Sci Rep; 2017 Mar; 7():45394. PubMed ID: 28345603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Transcriptional Dynamics Between T-cells and Macrophages as Determined by a Three-State Mathematical Model.
    DeMarino C; Cowen M; Pleet ML; Pinto DO; Khatkar P; Erickson J; Docken SS; Russell N; Reichmuth B; Phan T; Kuang Y; Anderson DM; Emelianenko M; Kashanchi F
    Sci Rep; 2020 Feb; 10(1):2227. PubMed ID: 32042107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 tat transcriptional activity is regulated by acetylation.
    Kiernan RE; Vanhulle C; Schiltz L; Adam E; Xiao H; Maudoux F; Calomme C; Burny A; Nakatani Y; Jeang KT; Benkirane M; Van Lint C
    EMBO J; 1999 Nov; 18(21):6106-18. PubMed ID: 10545121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components.
    Likhoshvai VA; Khlebodarova TM; Bazhan SI; Gainova IA; Chereshnev VA; Bocharov GA
    BMC Genomics; 2014; 15 Suppl 12(Suppl 12):S1. PubMed ID: 25564443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-time view of the TAR:Tat:P-TEFb complex at HIV-1 transcription sites.
    Molle D; Maiuri P; Boireau S; Bertrand E; Knezevich A; Marcello A; Basyuk E
    Retrovirology; 2007 May; 4():36. PubMed ID: 17537237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.
    Marcello A; Zoppé M; Giacca M
    IUBMB Life; 2001 Mar; 51(3):175-81. PubMed ID: 11547919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular RelB interacts with the transactivator Tat and enhance HIV-1 expression.
    Wang M; Yang W; Chen Y; Wang J; Tan J; Qiao W
    Retrovirology; 2018 Sep; 15(1):65. PubMed ID: 30241541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.
    Li C; Wang HB; Kuang WD; Ren XX; Song ST; Zhu HZ; Li Q; Xu LR; Guo HJ; Wu L; Wang JH
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.